251 related articles for article (PubMed ID: 6221530)
1. Pharmacological studies on OKY-1581: a selective thromboxane synthetase inhibitor.
Hiraku S; Wakitani K; Katsube N; Kawasaki A; Tsuboshima M; Naito J; Ujiie A; Komatsu H; Iizuka K
Adv Prostaglandin Thromboxane Leukot Res; 1983; 11():241-4. PubMed ID: 6221530
[No Abstract] [Full Text] [Related]
2. Endogenous prostacyclin contributes to the efficacy of a thromboxane synthetase inhibitor for preventing coronary artery thrombosis.
Aiken JW; Shebuski RJ; Miller OV; Gorman RR
J Pharmacol Exp Ther; 1981 Nov; 219(2):299-308. PubMed ID: 6270303
[No Abstract] [Full Text] [Related]
3. The effects of aspirin and OKY-1581 on the metabolism of exogenous arachidonic acid in rat alveolar macrophages.
Punnonen K; Uotila P; Mäntylä E
Res Commun Chem Pathol Pharmacol; 1984 Jun; 44(3):367-74. PubMed ID: 6431566
[TBL] [Abstract][Full Text] [Related]
4. [Effect of thromboxane synthetase inhibitors on the action of bronchoactive agents and on arachidonate metabolism in the guinea pig tracheobronchopulmonary system].
Kitamura S; Ishihara Y; Takaku F
Nihon Kyobu Shikkan Gakkai Zasshi; 1984 Jan; 22(1):3-8. PubMed ID: 6539836
[No Abstract] [Full Text] [Related]
5. Intravenous infusion of a selective inhibitor of thromboxane A2 synthetase in man: influence on thromboxane B2 and 6-keto-prostaglandin F1 alpha levels and platelet aggregation.
Yui Y; Hattori R; Takatsu Y; Nakajima H; Wakabayashi A; Kawai C; Kayama N; Hiraku S; Inagawa T; Tsubojima M
Circulation; 1984 Oct; 70(4):599-605. PubMed ID: 6434196
[TBL] [Abstract][Full Text] [Related]
6. Protective actions of a new thromboxane synthetase inhibitor in arachidonate induced sudden death.
Edmonds LC; Lefer AM
Life Sci; 1984 Oct; 35(17):1763-8. PubMed ID: 6434893
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological studies on the TXA2 synthetase inhibitor (E)-3-[p-(1H-imidazol-1-ylmethyl)phenyl]-2-propenoic acid (OKY-046).
Hiraku S; Taniguchi K; Wakitani K; Omawari N; Kira H; Miyamoto T; Okegawa T; Kawasaki A; Ujiie A
Jpn J Pharmacol; 1986 Jul; 41(3):393-401. PubMed ID: 3093741
[TBL] [Abstract][Full Text] [Related]
8. Pulmonary vascular responses to thromboxane A2 as unmasked by OKY-1581. A novel inhibitor of thromboxane synthesis.
Kadowitz PJ; Nandiwada PA; Spannhake EW; Rosenson RS; McNamara DB; Hyman AL
Chest; 1983 May; 83(5 Suppl):72S-74S. PubMed ID: 6404609
[No Abstract] [Full Text] [Related]
9. Effects of a selective inhibitor of thromboxane synthetase (OKY-1581) in humans.
Ito T; Ogawa K; Sakai K; Watanabe J; Satake T; Kayama N; Hiraku S; Naito J
Adv Prostaglandin Thromboxane Leukot Res; 1983; 11():245-51. PubMed ID: 6221531
[No Abstract] [Full Text] [Related]
10. [Effect of OKY-046, a thromboxane synthetase inhibitor, on renal thromboxane synthesis in spontaneously hypertensive rat].
Nakayama D; Ikeda T
Nihon Jinzo Gakkai Shi; 1988 Jan; 30(1):79-84. PubMed ID: 3386014
[No Abstract] [Full Text] [Related]
11. Biochemical and pharmacological evaluation of thromboxane synthetase inhibitors.
Gorman RR
Adv Prostaglandin Thromboxane Res; 1980; 6():417-25. PubMed ID: 6247892
[No Abstract] [Full Text] [Related]
12. Biology and biochemistry of thromboxane synthetase inhibitors.
Gorman RR
Adv Prostaglandin Thromboxane Leukot Res; 1983; 11():235-40. PubMed ID: 6221529
[No Abstract] [Full Text] [Related]
13. The effect of a thromboxane synthetase inhibitor, OKY-046, on urinary excretion of immunoreactive thromboxane B2 and 6-keto-prostaglandin F1 alpha in patients with ischemic cerebrovascular disease.
Uyama O; Nagatsuka K; Nakabayashi S; Isaka Y; Yoneda S; Kimura K; Abe H
Stroke; 1985; 16(2):241-4. PubMed ID: 3883580
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological manipulation of canine cyclooxygenase and thromboxane synthetase in vivo: differential renal and platelet recovery rates.
Oshima T; McCluskey ER; Honda A; Needleman P
J Pharmacol Exp Ther; 1984 May; 229(2):598-602. PubMed ID: 6425495
[TBL] [Abstract][Full Text] [Related]
15. Platelet thromboxane synthetase inhibitors with low doses of aspirin: possible resolution of the "aspirin dilemma".
Bertelé V; Falanga A; Tomasiak M; Dejana E; Cerletti C; de Gaetano G
Science; 1983 Apr; 220(4596):517-9. PubMed ID: 6682245
[TBL] [Abstract][Full Text] [Related]
16. Cardioprotective actions of a selective thromboxane synthetase inhibitor in acute myocardial ischemia.
Burke SE; Lefer DJ; Lefer AM
Arch Int Pharmacodyn Ther; 1983 Sep; 265(1):76-84. PubMed ID: 6686001
[TBL] [Abstract][Full Text] [Related]
17. OKY-1581, a potential selective thromboxane synthetase inhibitor.
Feuerstein N; Ramwell PW
Eur J Pharmacol; 1981 Feb; 69(4):533-4. PubMed ID: 7195815
[No Abstract] [Full Text] [Related]
18. Inhibition of human platelet thromboxane synthetase by 11a-carbathromboxane A2 analogs.
Gorman RR; Maxey KM; Bundy GL
Biochem Biophys Res Commun; 1981 May; 100(1):184-90. PubMed ID: 7196228
[No Abstract] [Full Text] [Related]
19. Effects of selective thromboxane synthetase inhibitor OKY-046 on plasma prostaglandins in patients with coronary artery disease during exercise.
Shikano M; Ogawa K; Ito T; Chen LS; Ito Y; Imaizumi M; Uno T; Tsutsumi S; Satake T
Adv Prostaglandin Thromboxane Leukot Res; 1985; 13():375-7. PubMed ID: 3159226
[No Abstract] [Full Text] [Related]
20. Effect of OKY-1581, a thromboxane synthetase inhibitor, on coronary thrombosis in the conscious dog.
Shea MJ; Driscoll EM; Romson JL; Pitt B; Lucchesi BR
Eur J Pharmacol; 1984 Oct; 105(3-4):285-91. PubMed ID: 6542526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
